Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria.
Animals
Anti-Bacterial Agents
/ administration & dosage
Bacteria
/ drug effects
Candida albicans
/ immunology
Candidiasis, Invasive
/ immunology
Coinfection
/ immunology
Granulocyte-Macrophage Colony-Stimulating Factor
/ immunology
Humans
Iatrogenic Disease
Immunotherapy
Interleukin-17
/ immunology
Mice
Th17 Cells
/ metabolism
Vancomycin
/ pharmacology
GM-CSF
IL-17A
antibiotics
invasive candidiasis
lymphocytes
trans-kingdom infections
vancomycin
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
13 07 2022
13 07 2022
Historique:
received:
19
08
2021
revised:
08
03
2022
accepted:
20
04
2022
pubmed:
15
5
2022
medline:
19
7
2022
entrez:
14
5
2022
Statut:
ppublish
Résumé
Antibiotics are a modifiable iatrogenic risk factor for the most common human nosocomial fungal infection, invasive candidiasis, yet the underlying mechanisms remain elusive. We found that antibiotics enhanced the susceptibility to murine invasive candidiasis due to impaired lymphocyte-dependent IL-17A- and GM-CSF-mediated antifungal immunity within the gut. This led to non-inflammatory bacterial escape and systemic bacterial co-infection, which could be ameliorated by IL-17A or GM-CSF immunotherapy. Vancomycin alone similarly enhanced the susceptibility to invasive fungal infection and systemic bacterial co-infection. Mechanistically, vancomycin reduced the frequency of gut Th17 cells associated with impaired proliferation and RORγt expression. Vancomycin's effects on Th17 cells were indirect, manifesting only in vivo in the presence of dysbiosis. In humans, antibiotics were associated with an increased risk of invasive candidiasis and death after invasive candidiasis. Our work highlights the importance of antibiotic stewardship in protecting vulnerable patients from life-threatening infections and provides mechanistic insights into a controllable iatrogenic risk factor for invasive candidiasis.
Identifiants
pubmed: 35568028
pii: S1931-3128(22)00219-0
doi: 10.1016/j.chom.2022.04.013
pmc: PMC9283303
mid: NIHMS1802941
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Interleukin-17
0
Vancomycin
6Q205EH1VU
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1020-1033.e6Subventions
Organisme : NIAID NIH HHS
ID : R00 AI141622
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA AI001175
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.
Références
Cell Host Microbe. 2019 Mar 13;25(3):404-417.e6
pubmed: 30870622
Bioinformatics. 2011 Nov 1;27(21):2957-63
pubmed: 21903629
Nat Neurosci. 2015 Jul;18(7):965-77
pubmed: 26030851
Clin Infect Dis. 1998 Jan;26(1):239-40
pubmed: 9455573
Cell Host Microbe. 2017 Dec 13;22(6):757-765.e3
pubmed: 29199098
Sci Transl Med. 2018 Oct 17;10(463):
pubmed: 30333238
Nature. 2008 Oct 9;455(7214):804-7
pubmed: 18724361
Crit Care. 2020 May 27;24(1):268
pubmed: 32460890
Cell. 2015 Oct 8;163(2):367-80
pubmed: 26411289
PLoS One. 2015 Dec 21;10(12):e0144854
pubmed: 26691591
Cell Host Microbe. 2008 Oct 16;4(4):337-49
pubmed: 18854238
Cell Host Microbe. 2015 May 13;17(5):662-71
pubmed: 25865369
Antimicrob Agents Chemother. 2015 Oct 19;60(1):252-7
pubmed: 26482315
Mucosal Immunol. 2015 Jul;8(4):886-95
pubmed: 25492473
Nat Med. 2020 Jan;26(1):59-64
pubmed: 31907459
Cell Host Microbe. 2013 Sep 11;14(3):318-28
pubmed: 24034617
J Allergy Clin Immunol. 2017 Jul;140(1):121-133.e3
pubmed: 28130148
Nat Med. 2015 Jul;21(7):808-14
pubmed: 26053625
Bioinformatics. 2018 Apr 15;34(8):1411-1413
pubmed: 29028892
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(8):3747-58
pubmed: 27415793
J Infect Dis. 2021 Apr 8;223(7):1295-1302
pubmed: 32798221
Nat Med. 2014 May;20(5):524-30
pubmed: 24747744
Immunity. 2021 Jan 12;54(1):68-83.e6
pubmed: 33238133
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Immunity. 2019 Feb 19;50(2):446-461.e9
pubmed: 30709742
J Exp Med. 2010 Feb 15;207(2):291-7
pubmed: 20123958
Nat Commun. 2017 Nov 15;8(1):1512
pubmed: 29142211
PLoS One. 2012;7(6):e39750
pubmed: 22768117
Science. 2013 Aug 2;341(6145):569-73
pubmed: 23828891
BMC Infect Dis. 2019 May 21;19(1):445
pubmed: 31113382
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503875
Mucosal Immunol. 2016 Mar;9(2):492-502
pubmed: 26349660
Cell. 2019 Aug 22;178(5):1088-1101.e15
pubmed: 31442402
Nat Rev Dis Primers. 2018 May 11;4:18026
pubmed: 29749387
Infect Immun. 2003 Oct;71(10):5756-64
pubmed: 14500497
Science. 2012 Jun 8;336(6086):1314-7
pubmed: 22674328
Microbiome. 2014 Feb 24;2(1):6
pubmed: 24558975
Scand J Infect Dis. 2001;33(10):784-6
pubmed: 11728053
Science. 2012 Jun 8;336(6086):1321-5
pubmed: 22674331
Nature. 2013 Jun 20;498(7454):367-70
pubmed: 23698366
N Engl J Med. 2007 Mar 1;356(9):904-10
pubmed: 17329697
Science. 2014 Mar 28;343(6178):1249288
pubmed: 24625929
Annu Rev Immunol. 2018 Apr 26;36:157-191
pubmed: 29237128
J Infect Dis. 2005 Jul 15;192(2):336-43
pubmed: 15962230
Clin Microbiol Infect. 2015 May;21(5):493.e1-4
pubmed: 25698658
J Antibiot (Tokyo). 2015 Feb;68(2):76-80
pubmed: 25138142
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Mucosal Immunol. 2020 Mar;13(2):216-229
pubmed: 31772323
Infect Immun. 2018 Nov 20;86(12):
pubmed: 30224553
Sci Transl Med. 2013 Jul 3;5(192):192ra85
pubmed: 23825301
Clin Infect Dis. 2014 Jul 1;59(1):81-4
pubmed: 24704721
Infect Immun. 2012 Dec;80(12):4216-22
pubmed: 22988015
J Innate Immun. 2011;3(2):180-99
pubmed: 21063074
Emerg Infect Dis. 2016 Jan;23(1):7-13
pubmed: 27983497
J Infect Dis. 2016 Jul 1;214(1):130-9
pubmed: 26917573
Am J Physiol Gastrointest Liver Physiol. 2014 Oct 15;307(8):G824-35
pubmed: 25059827
J Clin Microbiol. 2006 Oct;44(10):3647-58
pubmed: 17021093
J Infect Dis. 2016 Apr 15;213(8):1289-98
pubmed: 26908736
Eur J Immunol. 2018 Mar;48(3):464-470
pubmed: 29150834
Gut. 2016 Jul;65(7):1100-9
pubmed: 26045138
Sci Rep. 2015 Feb 03;5:8131
pubmed: 25644850
Cell Host Microbe. 2022 Jan 12;30(1):17-30.e9
pubmed: 34822777
Nature. 2008 Oct 9;455(7214):808-12
pubmed: 18716618
Clin Microbiol Infect. 2012 Feb;18(2):112-9
pubmed: 22032929
Eur J Microbiol Immunol (Bp). 2013 Mar;3(1):1-10
pubmed: 24265914
J Immunol. 2013 Jan 15;190(2):774-83
pubmed: 23241884
J Allergy Clin Immunol. 2018 Oct;142(4):1334-1338.e5
pubmed: 29890237
J Invest Dermatol. 2016 Dec;136(12):2356-2363
pubmed: 27476723
Proc Natl Acad Sci U S A. 2016 Dec 20;113(51):E8277-E8285
pubmed: 27930337
Ann Surg. 1994 Jul;220(1):68-76
pubmed: 8024361
Cancer. 2009 Oct 15;115(20):4745-52
pubmed: 19634156
mBio. 2018 Jun 5;9(3):
pubmed: 29871918
World J Surg. 2002 Mar;26(3):372-6
pubmed: 11865377
Cell Mol Gastroenterol Hepatol. 2018 Jul 11;6(3):347-348.e1
pubmed: 30182044
Science. 2011 Apr 1;332(6025):65-8
pubmed: 21350122
Immunity. 2013 Oct 17;39(4):676-86
pubmed: 24120361
Cancer. 2005 Jul 1;104(1):199-204
pubmed: 15929126
Med Mycol. 2014 Aug;52(6):555-64
pubmed: 25023483
PLoS Pathog. 2008 Feb 8;4(2):e35
pubmed: 18282097
Nat Immunol. 2021 Oct;22(10):1245-1255
pubmed: 34556884
Cell. 2009 Oct 30;139(3):485-98
pubmed: 19836068